
    
      Expected benefit(s) of the trial

        -  Improved quality of life during brachytherapy on account of the absence of radioactive
           seeds in the prostate:

             -  Fewer early urinary complications,

             -  No urine filtration,

             -  No post-operative use of condoms,

             -  No 2-year ban on cremation following treatment,

        -  Health cost savings,

        -  Acquisition of dosimetric data for inverse optimization.

      Predictable risk(s) for patients Predictable risks in the context of this trial involve the
      frequency of essentially urinary disorders.

      Methodology Open, monocentric, phase I-II study.
    
  